| Literature DB >> 27960515 |
Nikhil Rammohan1,2, Keith W MacRenaris1, Laura K Moore2, Giacomo Parigi3, Daniel J Mastarone1, Lisa M Manus1, Laura M Lilley1, Adam T Preslar1, Emily A Waters1, Abigail Filicko1, Claudio Luchinat3, Dean Ho4, Thomas J Meade1,2.
Abstract
The ability to track labeled cancer cells in vivo would allow researchers to study their distribution, growth, and metastatic potential within the intact organism. Magnetic resonance (MR) imaging is invaluable for tracking cancer cells in vivo as it benefits from high spatial resolution and the absence of ionizing radiation. However, many MR contrast agents (CAs) required to label cells either do not significantly accumulate in cells or are not biologically compatible for translational studies. We have developed carbon-based nanodiamond-gadolinium(III) aggregates (NDG) for MR imaging that demonstrated remarkable properties for cell tracking in vivo. First, NDG had high relaxivity independent of field strength, a finding unprecedented for gadolinium(III) [Gd(III)]-nanoparticle conjugates. Second, NDG demonstrated a 300-fold increase in the cellular delivery of Gd(III) compared to that of clinical Gd(III) chelates without sacrificing biocompatibility. Further, we were able to monitor the tumor growth of NDG-labeled flank tumors by T1- and T2-weighted MR imaging for 26 days in vivo, longer than was reported for other MR CAs or nuclear agents. Finally, by utilizing quantitative maps of relaxation times, we were able to describe tumor morphology and heterogeneity (corroborated by histological analysis), which would not be possible with competing molecular imaging modalities.Entities:
Keywords: MRI; Nanodiamonds; cancer; gadolinium; in vivo
Mesh:
Substances:
Year: 2016 PMID: 27960515 PMCID: PMC5482002 DOI: 10.1021/acs.nanolett.6b03378
Source DB: PubMed Journal: Nano Lett ISSN: 1530-6984 Impact factor: 11.189